Japanese drugmaker Eisai Co. Ltd. said on Monday it had submitted a marketing authorization application in Japan for its Alzheimer’s drug lecanemab, which was recently granted accelerated ...
Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer. Merck and Eisai on Friday ...
The collaboration seeks to prevent vision loss in BBS patients. The investigational gene therapy utilises a codon-optimised BBS1 AAV9 vector tailored to slow down vision loss caused by genetic defects ...
At its Unpacked event, Samsung showed off its upcoming "Project Moohan" AR/VR headset, which is designed to compete with the Vision Pro. Some users might even mistake the headset for a Vision Pro ...
A new artificial intelligence software aims to identify people at risk of dementia - during high street eye exams. Data ...
E-2086 is under clinical development by Eisai and currently in Phase I for Narcolepsy. According to GlobalData, Phase I drugs for Narcolepsy have an 80% phase transition success rate (PTSR) indication ...
The constraint has been a lack of good drugs to treat those patients. Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla, have begun the process of establishing a drug arsenal for ...
Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) accepted a marketing application for an injectable version of their Alzheimer ...
FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi subcutaneous autoinjector application. Leqembi's subcutaneous dosing allows Alzheimer's patients to administer weekly ...
Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. FDA has accepted Eisai's Biologics License Application for lecanemab-irmb, marketed as LEQEMBI, which is designed for subcutaneous ...
On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) for lecanemab-irmb (Leqembi) subcutaneous autoinjector (SC-AI ...